Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Cancer

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 198 results found since Jan 2013.

Cannabinoid pharmacology in cancer research: A new hope for cancer patients?
Abstract Cannabinoids have been used for many centuries to ease pain and in the past decade, the endocannabinoid system has been implicated in a number of pathophysiological conditions, such as mood and anxiety disorders, movement disorders such as Parkinson's and Huntington's disease, neuropathic pain, multiple sclerosis, spinal cord injury, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity, and osteoporosis. Several studies have demonstrated that cannabinoids also have anti-cancer activity and as cannabinoids are usually well tolerated and do not produce the typical toxic effects of...
Source: European Journal of Pharmacology - February 4, 2016 Category: Drugs & Pharmacology Authors: Javid FA, Phillips RM, Afshinjavid S, Verde R, Ligresti A Tags: Eur J Pharmacol Source Type: research

Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Abstract The relevance of tyrosine kinase inhibitors (TKIs) in the treatment of malignancies has been already defined. Aberrant activation of tyrosine kinase signaling pathways has been causally linked not only to cancers but also to other non-oncological diseases. This review concentrates on the novel plausible usage of this group of drugs in neurological disorders, such as ischemic brain stroke, subarachnoid hemorrhage, Alzheimer's disease, multiple sclerosis. The drugs considered here are representatives of both receptor and non-receptor TKIs. Among them imatinib and masitinib have the broadest spectrum of ther...
Source: Current Neuropharmacology - November 26, 2015 Category: Drugs & Pharmacology Authors: Gagalo I, Rusiecka I, Kocic I Tags: Curr Neuropharmacol Source Type: research

Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease
ConclusionAlthough patients with Crohn's disease were better informed on the detrimental effects of smoking, the awareness rate was still low.
Source: Alimentary Pharmacology and Therapeutics - October 5, 2015 Category: Drugs & Pharmacology Authors: C. De Bie, V. Ballet, N. Hendriks, S. Coenen, E. Weyts, G. Van Assche, S. Vermeire, M. Ferrante Tags: Original Scientific Paper Source Type: research

Medicinal uses, phytochemistry and pharmacology of the genus Uncaria
Conclusion Preliminary investigations on pharmacological properties of the Uncaria species have enlightened their efficacious remedy for hypertension, asthma, cancer, diabetes, rheumatism and neurodegenerative diseases. To ensure the safety and effectiveness in clinical application, research on bioactive compounds, pharmacological mechanisms and toxicity of the genus Uncaria as well as the stereo-chemistry and structure-activity relationships of indole alkaloids seem very important. Graphical abstract
Source: Journal of Ethnopharmacology - July 26, 2015 Category: Drugs & Pharmacology Source Type: research

The Toll-like Receptor Radical Cycle pathway: a new drug target in immune-related chronic fatigue.
Abstract In this review we discuss that peripheral and central activation of the Toll-like receptor 2/4 (TLR2/4) Radical Cycle may underpin the pathophysiology of immune-related chronic fatigue secondary to other medical diseases and conditions. The TLR Radical Cycle plays a role in illnesses and conditions that are disproportionately commonly comorbid with secondary chronic fatigue, including a) neuroinflammatory disorders, e.g. Parkinson's disease, stroke, depression, psychological stressors, and b) systemic disorders, e.g. (auto)immune disorders, chronic obstructive pulmonary disease, ankylosing spondylitis, ch...
Source: CNS and Neurological Disorders Drug Targets - March 17, 2015 Category: Drugs & Pharmacology Authors: Lucas K, Morris G, Anderson G, Maes M Tags: CNS Neurol Disord Drug Targets Source Type: research

Macrophages in Immunopathology of Atherosclerosis: a Target for Diagnostics and Therapy.
Abstract Immunopathology plays important roles in the development of different life-threatening diseases, such as atherosclerosis and its consequences (acute myocardial infarction and stroke), cancer, chronic inflammatory diseases. Effective modulation of the immune system may significantly increase the efficacy of prevention and therapy efforts. Currently there are no marketed drugs capable of normalizing immune system function in an intrinsic and comprehensive way. Here, we describe a test system designed for complex analysis of monocyte activity in individuals to diagnose immunopathology and monitor treatment e...
Source: Current Pharmaceutical Design - October 13, 2014 Category: Drugs & Pharmacology Authors: Orekhov AN, Sobenin IA, Gavrilin MA, Gratchev A, Kotyashova SY, Nikiforov NG, Kzhyshkowska J Tags: Curr Pharm Des Source Type: research

Natural anti-obesity agents
Publication date: Available online 14 June 2014 Source:Bulletin of Faculty of Pharmacy, Cairo University Author(s): Gamal A. Mohamed , Sabrin R.M. Ibrahim , Ehab S. Elkhayat , Riham Salah El Dine Obesity is a complex disease caused by the interaction of a myriad of genetic, dietary, lifestyle, and environmental factors, which favors a chronic positive energy balance, and leads to increased body fat mass. The incidence of obesity is rising at an alarming rate and is becoming a major public health concern with incalculable social costs. Indeed, obesity facilitates the development of metabolic disorders such as diabetes, hy...
Source: Bulletin of Faculty of Pharmacy, Cairo University - October 13, 2014 Category: Drugs & Pharmacology Source Type: research

The use of stimulant medications for non-core aspects of ADHD and in other disorders.
Abstract Psychostimulants play a central role in the management of ADHD. Here we review the evidence pertaining to the use of methylphenidate, dexamphetamine and related amphetamine salts, the prodrug lisdexamfetamine and modafinil for the management of comorbid ADHD and non-ADHD indications. There is a growing consensus that stimulant medications are helpful at improving the emotional dysregulation and lability, and oppositional and conduct symptoms that are often associated with ADHD. There is some evidence that psychostimulants may improve outcomes in those with treatment resistant depression, reduce negative s...
Source: Neuropharmacology - June 18, 2014 Category: Drugs & Pharmacology Authors: Sinita E, Coghill D Tags: Neuropharmacology Source Type: research

Cardiovascular effects of current and future anti-obesity drugs.
Abstract The prevalence of obesity increases and is associated with increases in co-morbidities e.g. type 2 diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, heart disease, stroke, asthma, several forms of cancer, depression, and may result in reduction of expected remaining lifespan. We have reviewed the adverse effects on the cardiovascular system of anti-obesity drugs now retracted from the market as well as the cardiovascular profile of current drugs and potential pathways which are considered for treatment of obesity. Fenfluramine, and sibutramine were withdrawn due to increased cardiovascular ...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U Tags: Curr Vasc Pharmacol Source Type: research

Increased carotid plaque burden in men with the fibrillin-1 2/3 genotype.
This article is protected by copyright. All rights reserved. PMID: 24837032 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Pharmacology and Physiology - May 17, 2014 Category: Drugs & Pharmacology Authors: De Basso R, Hedblad B, Carlson J, Persson M, Ostling G, Länne T Tags: Clin Exp Pharmacol Physiol Source Type: research

Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia‐reperfusion injury in heart
This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue‐8
Source: British Journal of Pharmacology - March 28, 2014 Category: Drugs & Pharmacology Authors: Rianne Nederlof, Otto Eerbeek, Markus W Hollmann, Richard Southworth, Coert J Zuurbier Tags: Review Source Type: research

Therapeutic potential of midkine in cardiovascular disease
This article is part of a themed section on Midkine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue‐4
Source: British Journal of Pharmacology - January 24, 2014 Category: Drugs & Pharmacology Authors: Kenji Kadomatsu, Péter Bencsik, Anikó Görbe, Csaba Csonka, Kazuma Sakamoto, Satoshi Kishida, Péter Ferdinandy Tags: REVIEW Source Type: research

Therapeutic Potential of Midkine in Cardiovascular Diseases
Abstract Ischemic heart disease, stroke and their pathological consequences are life‐threatening diseases that account for about half of deaths in developed countries. Pathology of these diseases includes cell death due to ischemia/reperfusion injury, vascular stenosis, and cardiac remodeling. The growth factor midkine plays a pivotal role in these events. Midkine shows an acute cytoprotective effect in ischemia/reperfusion injury at least in part via its anti‐apoptotic effect. Moreover, while midkine promotes endothelial cell proliferation, it also recruits inflammatory cells to lesions. These activities eventually en...
Source: British Journal of Pharmacology - November 28, 2013 Category: Drugs & Pharmacology Authors: Kenji Kadomatsu, Péter Bencsik, Anikó Görbe, Csaba Csonka, Kazuma Sakamoto, Satoshi Kishida, Péter Ferdinandy Tags: Review Article – Midkine Themed Issue Source Type: research

Targeting Hexokinase II to mitochondria to modulate energy metabolism and reduce ischemia‐reperfusion injury in heart
Summary Mitochondrially‐bound hexokinase II (mtHKII) has long been known to confer cancer cells with their resilience against cell death. More recently, mtHKII has emerged as a powerful protector against cardiac cell death. mtHKII protects against IR injury in skeletal muscle and heart, attenuates cardiac hypertrophy and remodelling, and is one of the major end‐effectors through which ischemic preconditioning protects against myocardial ischemia‐reperfusion injury. Mechanisms of mtHKII cardioprotection against reperfusion injury entail the maintenance of regulated OMM permeability during ischemia and reperfusion resu...
Source: British Journal of Pharmacology - August 30, 2013 Category: Drugs & Pharmacology Authors: Rianne Nederlof, Otto Eerbeek, Markus W Hollmann, Richard Southworth, Coert J Zuurbier Tags: Review Article Source Type: research

Systematic review evaluating cardiovascular events of the 5‐alpha reductase inhibitor – Dutasteride
Summary What is known and objectivesA recently published large, long‐term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of ‘cardiac failure’ was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta‐analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease. MethodsWe searched MEDLINE and EMBASE, unpublished articles identified through FDA/EMEA websites, study registers of pharmaceutical companies and reference list...
Source: Journal of Clinical Pharmacy and Therapeutics - July 1, 2013 Category: Drugs & Pharmacology Authors: Y. K. Loke, R. Ho, M. Smith, O. Wong, M. Sandhu, W. Sage, S. Singh Tags: Original Article Source Type: research